Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel H Solomon

Showing results (491-500 of 524) with videos related to

Pageof 53
Sort By:
The Journal of Rheumatology|August 1, 2025
Quality of Life in Adult Patients With SAPHO Syndrome and Chronic Nonbacterial Osteomyelitis, and Comparison to Chronic Rheumatic and Inflammatory DiseasesAleksander Lenert, Jenna Thomason, Melanie H Smith, et al.
ACR Open Rheumatology|May 1, 2021
Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET TrialJon T Giles, Pamela M Rist, Katherine P Liao, et al.
JAMA|November 8, 2011
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseasesCarlos G Grijalva, Lang Chen, Elizabeth Delzell, et al.
Annals of the Rheumatic Diseases|November 30, 2022
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritisDaniel H Solomon, Jon T Giles, Katherine P Liao, et al.
American Heart Journal|April 1, 2009
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritisMatthew C Becker, Thomas H Wang, Lisa Wisniewski, et al.
Plos One|August 15, 2019
Correction: Prevalence and predictors for sustained remission in rheumatoid arthritisYoon-Kyoung Sung, Kazuki Yoshida, Femke H M Prince, et al.
Arthritis and Rheumatism|May 28, 2010
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritisAltan Ercan, Jing Cui, Dereck E W Chatterton, et al.
Plos One|April 20, 2019
Prevalence and predictors for sustained remission in rheumatoid arthritisYoon-Kyoung Sung, Kazuki Yoshida, Femke H M Prince, et al.
Journal of Autoimmunity|August 3, 2024
Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologiesEmily G Oakes, Eilish Dillon, Katherine A Buhler, et al.
American Heart Journal|September 24, 2016
Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trialNiteesh K Choudhry, Thomas Isaac, Julie C Lauffenburger, et al.
Pageof 53

Showing results (491-500 of 524) with videos related to

Sort By:
Pageof 53
The Journal of Rheumatology|August 1, 2025
Quality of Life in Adult Patients With SAPHO Syndrome and Chronic Nonbacterial Osteomyelitis, and Comparison to Chronic Rheumatic and Inflammatory DiseasesAleksander Lenert, Jenna Thomason, Melanie H Smith, et al.
ACR Open Rheumatology|May 1, 2021
Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET TrialJon T Giles, Pamela M Rist, Katherine P Liao, et al.
JAMA|November 8, 2011
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseasesCarlos G Grijalva, Lang Chen, Elizabeth Delzell, et al.
Annals of the Rheumatic Diseases|November 30, 2022
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritisDaniel H Solomon, Jon T Giles, Katherine P Liao, et al.
American Heart Journal|April 1, 2009
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritisMatthew C Becker, Thomas H Wang, Lisa Wisniewski, et al.
Plos One|August 15, 2019
Correction: Prevalence and predictors for sustained remission in rheumatoid arthritisYoon-Kyoung Sung, Kazuki Yoshida, Femke H M Prince, et al.
Arthritis and Rheumatism|May 28, 2010
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritisAltan Ercan, Jing Cui, Dereck E W Chatterton, et al.
Plos One|April 20, 2019
Prevalence and predictors for sustained remission in rheumatoid arthritisYoon-Kyoung Sung, Kazuki Yoshida, Femke H M Prince, et al.
Journal of Autoimmunity|August 3, 2024
Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologiesEmily G Oakes, Eilish Dillon, Katherine A Buhler, et al.
American Heart Journal|September 24, 2016
Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trialNiteesh K Choudhry, Thomas Isaac, Julie C Lauffenburger, et al.
Pageof 53